At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 210 enrolled
Drug / intervention
IDP-123 Lotion +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac® (Tazarotene) Cream, in the Treatment of Acne Vulgaris
In Brief
A Phase 2 clinical trial evaluating IDP-123 Lotion, Tazorac Cream, and 2 other interventions for Acne Vulgaris. Completed, enrolled 210 participants across 16 sites.
Detailed Summary
Safety and Efficacy of IDP-123 Lotion (0.045% tazarotene) to Tazorac® (tazarotene) Cream, 0.1%, in the Treatment of Acne Vulgaris
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartNov 2015
Primary CompletionJul 2016
Study CompletionSep 2016
First PostedOct 2016
TodayJul 2026
First PostedOct 19, 2016
Enrollment StartNov 1, 2015
Primary CompletionJul 1, 2016
Study CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 9.7 years ago
Interventions
IDP-123 Lotiondrug
Lotion
Tazorac Creamdrug
Cream
Vehicle Lotiondrug
Lotion
Vehicle Creamdrug
Cream